These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2439704)

  • 1. Studies on suppressor T lymphocyte function in Graves' disease by 3H-thymidine interpolation.
    Fang WY; Ye WX
    J Tongji Med Univ; 1987; 7(1):40-3. PubMed ID: 2439704
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical significance of elevated serum triiodothyronine to thyroxine ratios in patients with Graves' disease treated with antithyroid drugs].
    Takamatsu J
    Nihon Naibunpi Gakkai Zasshi; 1983 Mar; 59(3):295-303. PubMed ID: 6190686
    [No Abstract]   [Full Text] [Related]  

  • 3. Decrease of immunoglobulin G-Fc receptor-bearing T lymphocytes in Graves' disease.
    Mori H; Amino N; Iwatani Y; Asari S; Izumiguchi Y; Kumahara Y; Miyai K
    J Clin Endocrinol Metab; 1982 Sep; 55(3):399-402. PubMed ID: 6178751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of T3-predominant Graves' disease].
    Lin LX
    Zhonghua Yi Xue Za Zhi; 1988 Feb; 68(2):79-81. PubMed ID: 2457417
    [No Abstract]   [Full Text] [Related]  

  • 5. T lymphocyte subpopulations in Graves' disease: relationship with clinical conditions.
    Bagnasco M; Canonica GW; Ferrini S; Biassoni P; Melioli G; Ferrini O; Giordano G
    Acta Endocrinol (Copenh); 1983 Feb; 102(2):213-9. PubMed ID: 6187169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anomalies of cellular immunity in Graves' disease treated by synthetic antithyroid drugs: effects on prognosis].
    Allannic H; Genetet N; Edan G; Merdrignac G; Simon M; Genetet B
    Pathol Biol (Paris); 1987 Dec; 35(10):1333-8. PubMed ID: 2449649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressor T lymphocyte function in Graves' disease.
    Hallengren B; Forsgren A
    Acta Endocrinol (Copenh); 1982 Nov; 101(3):354-8. PubMed ID: 6216711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-lymphocyte subsets in pregnant women with Graves' disease.
    Bizzarro A; Fontana A; De Bellis A; Daponte A; Iacono G; Peluso G
    Acta Endocrinol (Copenh); 1987 Feb; 114(2):218-27. PubMed ID: 2950710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific suppressor T cell function in a patient with Graves' disease and her healthy identical twin.
    Balázs C; Stenszky V; Kozma L; Farid NR
    Clin Endocrinol (Oxf); 1984 Jun; 20(6):683-93. PubMed ID: 6235984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term antithyroid drug therapy for intractable cases of Graves' disease.
    Shizume K
    Endocrinol Jpn; 1978 Aug; 25(4):377-9. PubMed ID: 81772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?
    Bogazzi F; Martino E; Bartalena L
    J Endocrinol Invest; 2003 Feb; 26(2):174-6. PubMed ID: 12739747
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
    Kallner G; Vitols S; Ljunggren JG
    J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal Graves' Eye Disease.
    Segal KL; Nelson CC
    Ophthalmology; 2017 May; 124(5):673. PubMed ID: 28433126
    [No Abstract]   [Full Text] [Related]  

  • 14. [Studies on the suppressor T cell function in patients with autoimmune thyroid diseases].
    Matsui J
    Nihon Naibunpi Gakkai Zasshi; 1984 Aug; 60(8):925-38. PubMed ID: 6096180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.
    Eliana F; Suwondo P; Asmarinah A; Harahap A; Djauzi S; Prihartono J; Pemayun TGD
    Acta Med Indones; 2017 Jul; 49(3):195-204. PubMed ID: 29093229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism.
    Tajiri J; Noguchi S; Morita M; Tamaru M; Murakami N; Kato R
    Endocrinol Jpn; 1991 Dec; 38(6):683-7. PubMed ID: 1726635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closer correlation between serum triiodothyronine and basal metabolic rate during antithyroid drug treatment in patients with Graves' disease.
    Hamada N; Miura T; Ban Y; Momotani N; Nishikawa Y; Ohno M; Morii H; Kitabatake S; Ito K
    Endocrinol Jpn; 1978 Apr; 25(2):117-22. PubMed ID: 78844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T lymphocyte sensitization and suppressor T lymphocyte defect in patients long after treatment for Graves' disease.
    How J; Topliss DJ; Strakosch C; Lewis M; Row VV; Volpé R
    Clin Endocrinol (Oxf); 1983 Jan; 18(1):61-71. PubMed ID: 6221835
    [No Abstract]   [Full Text] [Related]  

  • 20. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.